Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis (SAFESYNC NG)

16 november 2026 bijgewerkt door: Braile Biomedica Ind. Com. e Repr. Ltda.

Evaluation of the Safety and Clinical Performance of the Next-Generation SAFESYNC Balloon-Expandable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: A Prospective, Multicenter, Single-Arm Pivotal Study

This pivotal, prospective, multicenter (Brazil, Chile and Argentina), single-arm study will evaluate the safety and clinical performance of the Inovare® Safesync Next-Generation bioprosthetic heart valve, implanted by transfemoral transcatheter aortic valve implantation (TAVI) with the B-Delivery System, in patients aged 70 years or older with severe aortic stenosis and an indication for TAVI, regardless of surgical risk. The study will enroll 210 participants.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

210

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Clinical Research Department - Braile Biomédica
  • Telefoonnummer: +5517 21367000
  • E-mail: pesquisa@braile.com.br

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

70 jaar en ouder (Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Severe aortic valve stenosis diagnosed according to criteria established in current guidelines; Age ≥70 years, regardless of surgical risk; Indication for transcatheter aortic valve implantation (TAVI); Willing to participate and to sign the written informed consent form.

Exclusion Criteria:

Any condition considered a contraindication to implantation of a bioprosthetic heart valve (e.g., patient with an indication for a mechanical heart valve);

Known hypersensitivity or contraindication to any of the following that cannot be adequately managed with premedication:

  1. Aspirin, clopidogrel, or heparin (heparin-induced thrombocytopenia [HIT] or heparin-induced thrombocytopenia with thrombosis [HITTS]);
  2. Nitinol (titanium or nickel);
  3. Contrast media; Blood dyscrasias: leukopenia (white blood cell count <1,000/mm³), thrombocytopenia (platelet count <100,000 cells/mm³), history of coagulopathy, or hypercoagulable states; Active infection, including endocarditis; Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or need for mechanical hemodynamic support; Recent stroke or transient ischemic attack (within 6 months); History of gastrointestinal bleeding or other bleeding that precludes anticoagulant or antiplatelet therapy; Estimated life expectancy of less than 5 years; Other medical, social, or psychological conditions that, in the investigator's opinion, prevent the patient from providing consent or adequately complying with the protocol; Pre-existing prosthetic heart valve in the aortic position (biological or mechanical); Concomitant severe mitral or tricuspid valve disease; Hypertrophic obstructive cardiomyopathy; Percutaneous coronary intervention performed within 72 hours prior to the study procedure; Femoral artery diameter <5.5 mm (for Safesync 20 to 24 mm), <6.0 mm (for Safesync 26 and 28 mm), or <6.5 mm (for Safesync 30 mm); High risk of annular rupture or significant residual paravalvular leak due to severe calcification of the aortic valve or left ventricular outflow tract; High risk of coronary obstruction (coronary ostial height <10 mm with narrow sinuses of Valsalva [SOV], defined as a mean SOV diameter <3 mm larger than the bioprosthesis size), as determined by computed tomography angiography; Left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤30%; Severe chronic kidney disease, defined as glomerular filtration rate <30 mL/min/1.73 m².

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: INOVARE® SAFESYNC Next-Generation TAVI

Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Device Success According to VARC-3 Criteria
Tijdsspanne: 30 days after the procedure

Technical success; Absence of mortality; Absence of surgery or intervention related to the device or to major vascular, access-related, or cardiac structural complications; Intended valve performance, defined as mean transvalvular gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation.

30 days after the procedure

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Achieving Technical Success According to VARC-3 Criteria
Tijdsspanne: During the procedure

Defined as freedom from mortality; successful vascular access, delivery of the device, and retrieval of the delivery system; correct positioning of a single prosthetic heart valve in the intended anatomical location; and freedom from surgery or intervention related to the device or to a major vascular, access-related, or cardiac structural complication. Results will be reported as the number and percentage of participants achieving technical success.

During the procedure
Incidence and Severity of Paravalvular Leak
Tijdsspanne: 30 days, 6 months, 12 months, and annually through 5 years

Paravalvular leak will be assessed by transthoracic echocardiography and classified according to severity. The number and percentage of participants with paravalvular leak in each severity category will be reported.

30 days, 6 months, 12 months, and annually through 5 years
Mean Transvalvular Aortic Pressure Gradient Assessed
Tijdsspanne: 30 days, 6 months, 12 months, and annually through 5 years

Mean transvalvular aortic pressure gradient will be assessed by transthoracic echocardiography and reported in mmHg.

30 days, 6 months, 12 months, and annually through 5 years
Distribution of Participants by New York Heart Association Functional Class
Tijdsspanne: 30 days, 6 months, 12 months, and annually through 5 years

Functional status will be assessed using the New York Heart Association (NYHA) Functional Classification. The classification ranges from Class I to Class IV, where Class I represents no limitation of physical activity and Class IV represents inability to perform physical activity without symptoms and/or symptoms at rest. Higher NYHA classes indicate worse functional status. Results will be reported as the number and percentage of participants in each NYHA functional class.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of New Permanent Pacemaker Implantation
Tijdsspanne: 30 days, 6 months, 12 months, and annually through 5 years

New permanent pacemaker implantation following the index transcatheter aortic valve implantation procedure will be assessed. Results will be reported as the number and percentage of participants who undergo new permanent pacemaker implantation.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of All-Cause Mortality
Tijdsspanne: 30 days, 6 months, 12 months, and annually through 5 years

All-cause mortality will be assessed throughout follow-up. Results will be reported as the number and percentage of participants who die from any cause.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Stroke
Tijdsspanne: 30 days, 6 months, 12 months, and annually through 5 years

Stroke events will be assessed based on clinical neurological evaluation and classified according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants experiencing stroke.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve-Related Reintervention
Tijdsspanne: 30 days, 6 months, 12 months, and annually through 5 years

Bioprosthetic valve-related reintervention will be defined as any surgical or transcatheter intervention performed to treat dysfunction or failure of the implanted study valve. Results will be reported as the number and percentage of participants undergoing valve-related reintervention.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve Dysfunction According to VARC-3 Definitions
Tijdsspanne: 30 days, 6 months, 12 months, and annually through 5 years

Bioprosthetic valve dysfunction will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Bioprosthetic valve dysfunction includes structural valve deterioration, non-structural valve dysfunction, valve thrombosis, and endocarditis. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve dysfunction and according to the corresponding category.

30 days, 6 months, 12 months, and annually through 5 years
Incidence of Bioprosthetic Valve Failure According to VARC-3 Definitions
Tijdsspanne: 30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure

Bioprosthetic valve failure will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve failure.

30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 juli 2027

Studie voltooiing (Geschat)

1 juni 2032

Studieregistratiedata

Eerst ingediend

19 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

3 september 2026

Eerst geplaatst (Werkelijk)

8 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren